Leukemia Treatment

A leukemia diagnosis — whether for yourself or your child — demands immediate, accurate treatment. The type of leukemia, the stage, and the specific genetic markers in the cancer cells all determine what treatment is required. Across much of Africa and the Middle East, the diagnostic tools needed to identify these markers precisely are simply not available. Flow cytometry, cytogenetics, and molecular profiling are standard at India's leading cancer centres, but remain out of reach at most local hospitals in these regions. Without this information, the right treatment cannot be chosen. And in acute leukemia, where the disease progresses rapidly, delays in reaching the right treatment directly affect outcomes.

Leukemia is a cancer of the blood and bone marrow in which the body produces abnormal white blood cells that crowd out healthy cells. Treatment depends on the specific subtype: acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) require intensive chemotherapy given in phases of induction, consolidation, and maintenance. Chronic forms, including CML and CLL, are typically managed with targeted oral therapies such as tyrosine kinase inhibitors. In cases of relapse or high-risk disease, a bone marrow transplant may be required. Pediatric ALL, the most common childhood cancer, has a five-year survival rate above 90% when treated at specialist centres with current protocols.

Leukemia treatment in India at a JCI-accredited private hospital costs between $6,000 and $36,000 USD as of 2026, depending on the leukemia subtype, the treatment protocol required, and whether a bone marrow transplant is needed. This range covers diagnostics, chemotherapy cycles, targeted therapy, and hospital stays. For patients from regions where comparable specialist oncology care is available only at major private hospitals in South Africa or the Gulf, the cost difference is substantial. India's pricing reflects the structure of its healthcare system — high procedure volumes and lower institutional costs — not a lower standard of care.

Apollo Hospitals, BLK-Max Super Specialty Hospital, Medanta The Medicity, and Fortis Memorial Research Institute are all JCI-accredited and operate comprehensive hemato-oncology programmes. Medanta became one of the first private hospitals in India to offer CAR-T cell therapy for blood cancers, a therapy currently unavailable at most centres globally. Apollo Hospitals has completed over 1,500 bone marrow transplants across its network. Medanta achieves remission rates exceeding 75% in standard-risk AML, with three-year survival rates of 55 to 65% across all risk categories. At specialist centres in India, childhood ALL achieves five-year survival rates above 90% using current international protocols.

India's leukemia centres perform comprehensive molecular profiling — including 10-colour flow cytometry, high-resolution HLA typing, and next-generation sequencing — as a standard part of every new diagnosis as of 2026. This precision guides treatment decisions and identifies which patients qualify for newer targeted therapies, including FLT3 inhibitors, IDH inhibitors, and venetoclax combinations. These are therapies that are either unavailable or unaffordable in most of the regions from which patients travel to India.

MediVenza arranges your medical visa invitation letter, hospital selection, airport pickup, accommodation for you and your accompanying family member, interpreter support during all consultations, and full documentation for your local doctor when you return home. Our coordinator stays with your case from your first message to your post-return follow-up.

Want a clear picture before you decide?

Send your medical reports to [email protected] or WhatsApp +919899655596. Our team will review your case and advise on costs, timeline, and next steps within 24 hours. There is no obligation.

Send your medical reports to [email protected] or WhatsApp +919899655596 for assessment within 24 hours.

How Leukemia Is Treated in India

Treatment begins with a full diagnostic workup: blood tests, bone marrow biopsy, flow cytometry, cytogenetics, and molecular profiling. This takes two to four days and establishes the exact leukemia subtype and risk category before any treatment starts. Apollo, BLK-Max, Medanta, and Fortis all carry out this diagnostic process in-house.

• Induction chemotherapy: For acute leukemias, the first treatment phase uses intensive chemotherapy over four to six weeks to achieve remission by eliminating the majority of leukemia cells from the bone marrow.
• Consolidation and maintenance: Following remission, additional chemotherapy cycles strengthen the response. Maintenance therapy for some subtypes, particularly childhood ALL, continues for two to three years.
• Targeted therapy: For chronic leukemia subtypes or specific genetic mutations, oral targeted drugs are prescribed on an ongoing basis. India offers affordable generic versions of several first-line agents.
• Bone marrow transplant (if required): High-risk, relapsed, or refractory cases may be referred for allogeneic or haploidentical transplant at the same centre.

The initial treatment stay in India is typically three to eight weeks for acute leukemia, followed by outpatient cycles over several months. MediVenza arranges family accommodation near the hospital and interpreter support for all consultations throughout the treatment period.

Recovery and Ongoing Care After Leukemia Treatment

The timeline for returning home depends on your leukemia type and the treatment phase completed. After induction chemotherapy, most patients can travel home once blood counts stabilise and the treating oncologist confirms it is safe to do so. This is typically four to eight weeks after starting treatment. Consolidation cycles may require return visits to India, or your treating team may coordinate with a local oncologist to continue an equivalent protocol at home.

Follow-Up After Returning Home

You leave India with a complete discharge summary, your full diagnostic molecular report, a treatment summary, a medication schedule, and a recommended follow-up protocol. These documents give your local doctor everything needed to continue monitoring your blood counts, order appropriate tests, and manage your medications. For patients on long-term oral targeted therapy, your India-based oncologist can advise on generic equivalents available locally.

Remote consultations with your India-based hemato-oncology team are available throughout your ongoing treatment. MediVenza coordinates any communication between your local doctor and your treating team when needed.

For patients requiring bone marrow transplant, a separate recovery protocol applies. MediVenza will advise on this in detail as part of your treatment planning.